Advanced in Pancreatic Islet Cell Tumor

Naftali A. Stern

Dr Ya'ackov Klachkin 35 St, 6997801, 
Tel Aviv, TA, IL 
Advanced in Pancreatic Islet Cell Tumor
Dr Ya'ackov Klachkin 35 St, 6997801, 
Tel Aviv, TA, IL 
OverviewLocationsClinical Research

Overview

Naftali Stern practices in Tel Aviv, Israel. Mr. Stern is rated as an Advanced expert by MediFind in the treatment of Pancreatic Islet Cell Tumor. His top areas of expertise are Metabolic Syndrome, Hypertension, Obesity, Hormone Replacement Therapy (HRT), and Thyroidectomy.

His clinical research consists of co-authoring 117 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 3 articles in the study of Pancreatic Islet Cell Tumor.

Gender
Male

Locations

Dr Ya'ackov Klachkin 35 St, 6997801, Tel Aviv, TA 69978, Israel
Other Locations
6 Weizmann Street, Tel Aviv, TA 64239, Israel

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

The Effect of a Circuit Resistance Training, Empagliflozin or Vegeterranean Diet on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial)
The Effect of a Circuit Resistance Training, Empagliflozin or Vegeterranean Diet on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial)
Enrollment Status: Completed
Publish Date: September 04, 2025
Intervention Type: Behavioral, Drug
Study Drug: Empagliflozin
Study Phase: Phase 4
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Efficacy and Safety of LY3298176 Once Weekly Versus Insulin Glargine in Patients With Type 2 Diabetes and Increased Cardiovascular Risk (SURPASS-4)
Enrollment Status: Completed
Publish Date: February 14, 2022
Intervention Type: Drug
Study Drugs: Tirzepatide, Insulin Glargine
Study Phase: Phase 3
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
A Multicenter Dose-Titration Open-Label Study of Nevanimibe Hydrochloride for the Treatment of Classic Congenital Adrenal Hyperplasia
Enrollment Status: Terminated
Publish Date: March 04, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 2 Less Clinical Trials

117 Total Publications

Cortisol Secretion in Obesity Revisited: Lower Basal Serum and Salivary Cortisol with Diminished Cortisol Response to the Low Dose ACTH Challenge.
Cortisol Secretion in Obesity Revisited: Lower Basal Serum and Salivary Cortisol with Diminished Cortisol Response to the Low Dose ACTH Challenge.
Journal: Obesity facts
Published: October 08, 2024

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Stern's expertise for a condition
ConditionClose
    View All 9 Advanced Conditions
    View All 34 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile